Novartis recently announced positive Phase III results from its KALUMA study of GanLum (ganaplacide/lumefantrine), a new ...
Despite a 2% rise in adjusted EBITDA and increased green energy capacity, Ignitis Group AB faces profit declines and cash flow hurdles.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback